Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
velpatasvir
- Development stage
- Phase 4
- Lead developer
- Gilead Sciences
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Velpatasvir is a direct-acting antiviral (DAA) medication used as part of combination therapy, most commonly with sofosbuvir, for the treatment of chronic hepatitis C virus (HCV) infection across all major genotypes. It acts as an inhibitor of the HCV nonstructural protein 5A (NS5A), a viral protein essential for HCV replication and assembly. By binding to NS5A, velpatasvir disrupts viral RNA replication and virion assembly, thereby inhibiting the spread of HCV within the body. Velpatasvir is highly protein-bound (>99.5%), metabolized primarily by CYP2B6, CYP2C8, and CYP3A4 enzymes in the liver, and excreted mainly via feces. The drug was developed by Gilead Sciences[1][5][6].
- Brand names
- Epclusa
02
Targets
NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))
Beyond the preview
Go deeper on velpatasvir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on velpatasvir.